CN1593554A - 一种治疗呼吸***疾病的药物 - Google Patents
一种治疗呼吸***疾病的药物 Download PDFInfo
- Publication number
- CN1593554A CN1593554A CN 200410026269 CN200410026269A CN1593554A CN 1593554 A CN1593554 A CN 1593554A CN 200410026269 CN200410026269 CN 200410026269 CN 200410026269 A CN200410026269 A CN 200410026269A CN 1593554 A CN1593554 A CN 1593554A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- treating
- respiratory system
- system diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241000237636 Pheretima Species 0.000 claims description 5
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 208000006673 asthma Diseases 0.000 abstract description 12
- 230000001154 acute effect Effects 0.000 abstract description 10
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 8
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000596154 Belamcanda Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001062009 Indigofera Species 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 150000003851 azoles Chemical group 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003504 ach effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 例数(n) | 给药前咳嗽反应 | 给药后咳嗽反应 | ||
潜伏期(秒) | 次数/分 | 潜伏期(秒) | 次数/分 | |||
对照组 | 10 | 102.1±37.2 | 46±27 | 116.2±31.2 | 41±23 | |
小剂量组 | 5 | 10 | 96.8±37.2 | 31±23 | 87.7±35.1 | 23±20 |
大剂量组 | 10 | 10 | 57.0±13.8 | 41±23 | 117.2±35.2** | 20±18* |
阳性对照组 | 0.01 | 10 | 44.5±7.8 | 54±10 | 77.8±28.9** | 14±10* |
组别 | 动物数 | 蓝染级别评分 |
对照组 | 10 | 2.4±0.8 |
小剂量组 | 10 | 1.8±0.7 |
大剂量组 | 10 | 1.7±0.7 |
阳性组 | 10 | 1.6±0.6 |
水对照组 | —— | —— | —— | —— | —— | —— |
小剂量组 | 8 | 7 | —— | 8 | 8 | 7 |
大剂量组 | 10 | 9 | 7 | 10 | 8 | 9 |
红霉素 | 22 | 15 | 30 | 25 | 25 | 25 |
庆大霉素 | 28 | 7 | 25 | 24 | 20 | 14 |
组别 | 动物数(只) | 抗体效价 |
生理盐水 | 13 | 1940.9±4.3 |
4.0%的药物 | 14 | 1949.9±4.5 |
8.0%的药物 | 13 | 1859.6±4.0 |
环磷酰胺 | 11 | 1099.1±9.5** |
左旋米唑 | 14 | 2517.9±0.3** |
组别 | 动物(只) | OD(540nm) |
生理盐水 | 11 | 1.5±0.3 |
4.0%的药物 | 13 | 1.5±0.1 |
8.0%的药物 | 14 | 1.6±0.2 |
环磷酰胺 | 13 | 1.4±0.3 |
左旋咪唑 | 14 | 1.7±0.3 |
组别 | 动物数(只) | 花节 |
生理盐水组 | 12 | 10.4±3.6 |
4.0%的药物 | 13 | 8.7±3.6 |
8.0%的药物 | 13 | 9.1±3.6 |
环磷酰胺 | 13 | 8.1±3.5 |
左旋咪唑 | 14 | 9.4±2.5 |
组别 | 动物数(只) | ANAE |
生理盐水 | 14 | 49.2±8.8 |
4.0%的药物 | 11 | 53.0±10.2 |
8.0%的药物 | 13 | 50.9±8.2 |
环磷酰胺 | 14 | 47.9±16.0 |
左旋咪唑 | 13 | 56.3±7.4 |
组别 | 动物数 | SGPT(U) | SGOT(U) | 总蛋白(g/L) | 白蛋白(g/L) |
对照组 | 20 | 83±14 | 64±22 | 68±25 | 36±17 |
小剂量组 | 20 | 88±16 | 76±18 | 72±14 | 32±14 |
中剂量组 | 20 | 96±22 | 68±16 | 77±14 | 40±12 |
大剂量组 | 20 | 99±24 | 72±24 | 62±18 | 42±22 |
组别 | 动物数 | 血浆尿素氮含量mg% | 肌酐含量mg% |
对照组 | 20 | 11.6±2.7 | 1.2±0.6 |
小剂量组 | 20 | 8.6±1.6 | 1.4±0.4 |
中剂量组 | 20 | 8.7±2.5 | 0.9±0.6 |
大剂量组 | 20 | 8.7±2.4 | 1.0±0.6 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410026269 CN1259082C (zh) | 2004-06-24 | 2004-06-24 | 一种治疗呼吸***疾病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410026269 CN1259082C (zh) | 2004-06-24 | 2004-06-24 | 一种治疗呼吸***疾病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1593554A true CN1593554A (zh) | 2005-03-16 |
CN1259082C CN1259082C (zh) | 2006-06-14 |
Family
ID=34663878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410026269 Expired - Lifetime CN1259082C (zh) | 2004-06-24 | 2004-06-24 | 一种治疗呼吸***疾病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1259082C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396486B (zh) * | 2007-09-26 | 2011-06-22 | 北京亚东生物制药有限公司 | 治疗咳喘病的中药组合物及其制备方法和质量控制方法 |
CN102727733A (zh) * | 2012-07-05 | 2012-10-17 | 许瑞琴 | 一种用于治疗慢性支气管炎的中药 |
CN104288234A (zh) * | 2014-10-29 | 2015-01-21 | 扶绥县生产力促进中心 | 防治羊呼吸***疾病的中药制剂及其生产方法 |
CN107412462A (zh) * | 2017-03-09 | 2017-12-01 | 陕西东科制药有限责任公司 | 一种黄龙咳喘胶囊的制备方法 |
CN109276625A (zh) * | 2018-10-25 | 2019-01-29 | 济川药业集团有限公司 | 一种黄龙咳喘糖浆及其制备方法 |
-
2004
- 2004-06-24 CN CN 200410026269 patent/CN1259082C/zh not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396486B (zh) * | 2007-09-26 | 2011-06-22 | 北京亚东生物制药有限公司 | 治疗咳喘病的中药组合物及其制备方法和质量控制方法 |
CN102727733A (zh) * | 2012-07-05 | 2012-10-17 | 许瑞琴 | 一种用于治疗慢性支气管炎的中药 |
CN102727733B (zh) * | 2012-07-05 | 2013-10-16 | 许瑞琴 | 一种用于治疗慢性支气管炎的中药 |
CN104288234A (zh) * | 2014-10-29 | 2015-01-21 | 扶绥县生产力促进中心 | 防治羊呼吸***疾病的中药制剂及其生产方法 |
CN107412462A (zh) * | 2017-03-09 | 2017-12-01 | 陕西东科制药有限责任公司 | 一种黄龙咳喘胶囊的制备方法 |
CN107412462B (zh) * | 2017-03-09 | 2020-09-04 | 陕西东科制药有限责任公司 | 一种黄龙咳喘胶囊的制备方法 |
CN109276625A (zh) * | 2018-10-25 | 2019-01-29 | 济川药业集团有限公司 | 一种黄龙咳喘糖浆及其制备方法 |
CN109276625B (zh) * | 2018-10-25 | 2021-06-04 | 济川药业集团有限公司 | 一种黄龙咳喘糖浆及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1259082C (zh) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20130013712A (ko) | 생약추출물을 포함하는 동물의 설사병 예방 및 치료용 약제학적 조성물 및 그의 제조방법 | |
CN102028795B (zh) | 用于畜禽细菌性疾病的白头翁颗粒剂、制备方法和预混料 | |
US20190104757A1 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
CN103583898B (zh) | 一种预防断奶仔猪多***衰竭综合征的中草药饲料添加剂及其猪饲料 | |
CN1813868A (zh) | 一种治疗和改善慢性疲劳综合症的组合物及其制备方法 | |
CN103690538B (zh) | 具有抗禽畜支原体活性的中药提取物、中药组合物 | |
CN103083510A (zh) | 一种提高禽免疫功能的中药口服液及其制备方法 | |
CN1425447A (zh) | 一种治疗小儿食积咳嗽的中药组合物及其制备方法 | |
CN102058810B (zh) | 清肺定喘化痰中成药 | |
CN1259082C (zh) | 一种治疗呼吸***疾病的药物 | |
CN102357105A (zh) | 一种具有免疫增强作用的组合物及其应用 | |
CN101856415B (zh) | 治疗鸡呼吸道传染病的中草药口服液 | |
CN103768157A (zh) | 一种兽用抗病毒中药紫芪泡腾颗粒药物及其制备方法 | |
CN1957997A (zh) | 一种具有解肌清热、止泻止痢功能的兽用复方药剂及其制法 | |
CN111617200B (zh) | 一种用于治疗和预防肉鸡肺动脉高压的中药制剂及其制备方法 | |
CN108553504A (zh) | 参芪粉及其制备方法 | |
CN110251538B (zh) | 瑶药石油菜提取物在制备治疗克雷伯杆菌感染引起的肺炎药物中的应用 | |
CN106075241A (zh) | 一种仔猪保健促生长中药组合物及其制备方法 | |
CN101085048B (zh) | 一种兽用清毒中药及其制备方法 | |
CN109833366A (zh) | 一种中药组合物在制备改善免疫作用的药物中的应用 | |
CN109731016A (zh) | 一种治疗乳腺癌的中药组合物及其制备方法与药物 | |
CN108743693A (zh) | 一种仔猪保健促生长中药组合物、制备方法及其应用 | |
CN104013650B (zh) | 地衣芽孢杆菌与中药多糖组合物及其制剂 | |
CN102406740B (zh) | 一种治疗家禽组织滴虫病的纯中药组合物及其制备方法 | |
CN1634340A (zh) | 一种防治少儿呼吸***疾病的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YANGLING DONGKE MEDICINE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YANGLING MEDICINE PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee after: Yangling Dongke Maidisen Pharmaceutical Co.,Ltd. Address before: No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: YANGLING MAIDISEN PHARMACEUTICAL Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI DONGKE PHARMACEUTICAL LLC Free format text: FORMER OWNER: DONGKE MAIDISEN PHARMACEUTICAL CO., LTD., YANGLING Effective date: 20141230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141230 Address after: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee after: SHAANXI DONGKE PHARMACEUTICAL Co.,Ltd. Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: Yangling Dongke Maidisen Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060614 |